

**Supplemental Information**

**Cancer-secreted exosomal miR-1468-5p promotes  
tumor immune escape via the immunosuppressive  
reprogramming of lymphatic vessels**

**Chenfei Zhou, Wenfei Wei, Jing Ma, Yang Yang, Luojiao Liang, Yanmei Zhang, Zici  
Wang, Xiaojing Chen, Lei Huang, Wei Wang, and Sha Wu**

1    **Supplemental figures and legends**




Figure S1

2

3    **Supplementary Figure S1. Siha and hCEp successfully were transfected with**  
4    **lentiviral-CD63-GFP, related to Fig. 3.** Representative micrographs of Siha and  
5    hCEp transfected with lentiviral-CD63-GFP.

6




Figure S2

7

8    **Supplementary Figure S2. miR-1468-5p mimics contributed to PD-L1 expression**  
9    **and tube formation of HDLECs, related to Fig. 4.** Flow cytometry analysis of PD-  
10 L1 expression and tube formation assay in HDLECs treated with miR-1468-5p mimics

11 or NC. Scale bar, 10  $\mu$ m.

12




Figure S3

13

14 **Supplementary Figure S3. Cancer cells reprogrammed HDLECs by transferring**  
15 **exosomal miR-1468-5p to HDLECs, related to Fig. 4.** (A) qRT-PCR analysis of miR-  
16 1468-5p expression in HDLECs and Siha both stably transfected with lentiviral anti-  
17 1468-5p or NC. (B) Flow cytometry analysis of PD-L1 expression and tube formation  
18 assay in HDLECs/anti-1468-5p or HDLECs/anti-NC in the presence of hCEp-exo or  
19 Siha-exo. Scale bar, 10  $\mu$ m. (C and D) Quantification of PD-L1 expression (C) and tube  
20 formation (D) in HDLECs/anti-1468-5p or HDLECs/anti-NC in the presence of hCEp-  
21 exo or Siha-exo. Error bars represent the mean  $\pm$  SD of three independent experiments.

22 \*\*\*P < 0.001.

23




Figure S4

24

25 **Supplementary Figure S4. Flow cytometry analysis of PD-L1 and HLA-A24**  
 26 **expression, related to Fig. 5.** (A) Flow cytometry analysis of PD-L1 expression on  
 27 Siha/anti-NC and Siha/anti-1468-5p. (B) Flow cytometry analysis of CD8<sup>+</sup> T cells  
 28 amplification *in vivo* at indicated time point. (C) Flow cytometry analysis of HLA-A24  
 29 expression on Siha/anti-1468-5p, HDLECs, and CD8<sup>+</sup> T cells. Error bars represent the  
 30 mean  $\pm$  SD of three independent experiments. \*\*\*, P<0.001.

31




Figure S5

32

33 **Supplementary Figure S5. miR-1468-5p directly targets HMBOX1 in HDLECs**

34 **reprogramming, related to Fig. 6.** (A) qRT-PCR analysis of HMBOX1 expression in

35 HDLECs transfected with SiHMBOX1 or SiRNA. (B) Flow cytometry analysis of PD-

36 L1 and tube formation assay in HDLECs treated with SiHMBOX1 or SiRNA. Scale

37 bar, 10  $\mu$ m. (C) qRT-PCR analysis of HMBOX1 expression in HDLECs transfected

38 with HMBOX1 or vector. Error bars represent the mean  $\pm$  SD of three independent

39 experiments. \*\*\*, P<0.001.

40




Figure S6

41

42 **Supplementary Fig S6. JAK/STAT inhibitor neutralizes the effect of exosomal  
43 miR-1468-5p-induced CD8<sup>+</sup> T cell immunosuppression *in vivo*, related to Fig. 7.**

44 (A) Representative micrographs of CD8, PD-1, lymphatics, and PD-L1  
45 immunofluorescence staining in sections of xenograft tumors. Scale Bar: 20  $\mu$ m. (B)  
46 Quantification of CD8, PD-1, lymphatics, PD-L1, PD-1<sup>+</sup> CD8, and PD-L1<sup>+</sup> lymphatics  
47 expression in indicated groups. Error bars represent the mean  $\pm$  SD of three independent

48 experiments. \*\*, P<0.01; \*\*\*, P<0.001.

49

50 **Supplementary Tables**

51 **Table S1. Detailed primer sequences in the study**

52

	Forward	Reverse
MCMBP	CTGCCCAGCAATACTTCCCTT	TTCTGCCACGTTATGAGGTTG
ZNF501	AACTTTCCGCAAACAAGCACA	TCCCCACATCCAACACACTCATA
HMBOX1	CACCAACTCGCTACCATGCAA	TCCGATTGGCAAGAAAGGCTT
PRRT2	TTCTGTCTGAGAGTGTAGGGG	CAGGCTACCTCGGGGAGAT
SV2A	TATTCCCGAACGATCGTACTCCC	GCCCTCAGTAGCATCACTGG
MLH3	TCTCTCACTCATGCACCCCTTC	TCGGGAACATACGTCTTGTT
LCORL	GAGGAGCTATCATCTCAGGGC	TGAGCAACTAGGGGAATGTTAGG
GAPDH	CCATCAATGACCCCTTCATTGACC	GAAGGCCATGCCAGTGAGCTTCC
SiARID2	GGAGAUGGUUCUCAUUUAATT	UUAAAUGAGAACCAUCUCCTT
SiRNA	GCAGUUGUUGCACAGGUATT	UUACCUGUGCAACAAACUGCTT
HBS1	CTTCCAGGAGAGAACGCCGTCT	GCTGTAATTGCACACGTGTTGTG
HBS2	CTCGCACGACAATCGGAATCAC	CAGATTGGGAGCTCTGGACCT
HBS3	CCAGCCTCAGTTCTTCCGC	CGCCCTGCTGTCCCCGAA
HBS4	TCTGAGAGCTGTCTGTAGAGGGC	CTACTGCTCCGTAGGCATC

53